UTI

Reimbursement / Regulatory Changes

In the interest of improved patient safety, the Centers for Medicare and Medicaid Services (CMS) has introduced major changes to its reimbursement policy, targeting catheter-associated UTI and eight other healthcare-acquired conditions.

These changes include the introduction of the Present on Admission (POA) Indicator, a mechanism for hospitals to identify pre-existing conditions at the time of admission.

Conditions not documented as pre-existing, are treated as hospital-acquired and are not subject to reimbursement.

Private payers are introducing similar reimbursement policies regarding healthcare-associated conditions, placing up to 90% of hospital admissions at risk for receiving reduced reimbursement.

In the United States, these growing regulatory challenges have increased the need for complete urinalysis. Iris Diagnostics offers a comprehensive solution to optimize this process.

To request additional information about the Iris UTI Management Solution, please contact your local Iris Sales manager, or Click Here

The True Cost of UTI Treatment

Hospitals are faced with the decision to begin POA Indicator testing or bear the burden of non-reimbursable cost associated with treating a symptomatic UTI, including those costs attributed to extended complications, such as septicemia, and loss of reimbursement.

The Iris UTI Management Solution provides a cost-effective mechanism to document pre-existing UTI, at time of admission, and fulfill the POA Indicator requirement to protect reimbursements, at a substantial cost savings over treatment of symptomatic UTI.

Make A Clinically Relevant
Assessment of UTI

The Iris UTI Management Solution uses the Iris Urinalysis Workcell to analyze patient samples for five important urine chemistry and urine microscopy results. These results provide the laboratory and the physician a comprehensive understanding of the patient sample, to make a clinically relevant assessment if UTI may be present, and if the sample is a candidate for urine culture.

The five Iris Workcell bacteriuria indicators are WBC, Leukocyte esterase, Bacteria, Nitrite, and All Small Particles.

Laboratories use a combination of these five parameters to quickly assess patient samples for possible UTI, providing a faster turnaround time of results, reducing the workload for the Microbiology lab, and improving lab productivity.

Recent publications from Europe demonstrate the effective use of iQ^®200, in a clinical setting, as an accurate screening method for UTI. Each paper outlines the UTI screening strategy; including the parameters used and the level of accuracy achieved when using iQ200 as a screening tool for Bacteriuria.

Streamline the UTI Testing Process

The Iris UTI Management Solution provides a fast, accurate method of automated UTI testing, based upon a comprehensive set of clinically relevant urinalysis results, to protect reimbursement revenues, reduce cost, and streamline your UTI testing process, to improve lab productivity.

Accurate UTI Screening Information

Combined urine chemistry and microscopy results provide a more complete understanding of patient UTI status.

Walk-away automation improves laboratory productivity

Technologists can focus on other tasks; allows the laboratory to manage an increased workload without increasing headcount.

Reduced burden on Microbiology Laboratory

Reduction in the number of patient samples that require urine culture.

Fast turnaround time of results

Patient can receive appropriate treatment more quickly, reducing the need for non-specific antibiotic treatment.

NEW: Bacteriuria Reports

Reports are designed to streamline the UTI testing workflow by generating work lists of possible UTI patient sample values for review and possible release or reflex to Microbiology for urine culture analysis, based upon user-defined thresholds.

The Bacteriuria Reports display patient sample identification and a summary of combined urine chemistry and microscopy values for Leukocyte Esterase, Nitrite, White Blood Cells (WBC), Bacteria, and All Small Particles (ASP), consistent with the on-screen Bacteriuria Checklist. Results can be reviewed on-screen, or printed out for future reference.

Bacteriuria Reports

Bacteriuria Positive Reports allow customers to generate a work list of possible UTI screen positive patients for review and possible reflex to culture based upon user-defined thresholds.

Bacteriuria Negative Reports generate a patient list of possible UTI negative results for review and release.